Lambert-Eaton Myasthenic Syndrome (LES)

Catalyst Pharmaceutical Partners to Present at the 26th Annual ROTH Conference - MarketWatch

The Herald | HeraldOnline.com Catalyst Announces Initiation of an Expanded Access Program to Provide Firdapse at No Cost to   ... CORAL GABLES, Fla., Apr 23, 2014 (BUSINESS WIRE) -- Catalyst Pharmaceutical Partners, Inc. announced today it has begun the process required to establish an expanded access program (EAP) to make available in the United States its investigational potassium channel inhibitor, Firdapse™ (amifampridine phosphate or 3,4-DAP phosphate), to patients diagnosed with  Lambert-Eaton Myasthenic Syndrome (LEMS)  through their neuromuscular disease specialists. The product, currently in Phase 3 development, will be provided at no cost until sometime after approval. Program enrollment will begin in the next few months, pending FDA review and approvals. “As part of our ongoing commitment to the LEMS community, we are making Firdapse available to those who would like access to this investigational drug, but are unable to participate in clinical studies or tra